Sato K, Yoo Y C, Mochizuki M, Saiki I, Takahashi T A, Azuma I
Institute of Immunological Science, Hokkaido University, Sapporo.
Jpn J Cancer Res. 1995 Apr;86(4):374-82. doi: 10.1111/j.1349-7006.1995.tb03067.x.
We investigated the effect of a synthetic lipid A analogue with low endotoxicity, DT-5461, on the neovascularization induced by B16-BL6 melanoma in syngeneic mice. A systemic single administration of DT-5461 caused a marked decrease in the number of vessels oriented toward the tumor mass and in the tumor size during the early phase of vasculogenesis (on day 4 after tumor inoculation), with little or no inhibition in the following phases. Multiple i.v. administrations of DT-5461 at intervals of 4 days (an effective schedule for inhibiting tumor metastasis) significantly reduced the number of capillary vessels and tumor growth over a period of 14 days after the tumor implantation. Multiple systemic administrations of DT-5461 on days 1, 5 and 9 after tumor inoculation caused a high production of endogenous tumor necrosis factor-alpha (TNF-alpha) in tumor sites although this treatment modality induced a low production in serum of tumor-bearing mice. Tumor homogenate from mice treated with DT-5461 suppressed the proliferation of endothelium in vitro, whereas sera from animals given DT-5461 had little effect. Furthermore, the antiproliferative effect of the tumor homogenate from mice treated with DT-5461, was completely abrogated by anti-mTNF-alpha monoclonal antibody (mAb). The anti-angiogenic effect of DT-5461 was also completely abrogated by rabbit anti-mouse tumor necrosis factor-alpha (anti-mTNF-alpha) antiserum, whereas the inhibition of tumor growth by DT-5461 was only slightly diminished. Tumor homogenate from mice treated with DT-5461 suppressed the proliferation of endothelium in vitro, whereas sera from animals given DT-5461 had little effect. Furthermore, the antiproliferative effect of the tumor homogenate from mice treated with DT-5461 was completely neutralized by anti-mTNF-alpha mAb. Multiple i.v. administrations of DT-5461 after s.c. implantation of B16-BL6 cells significantly inhibited the growth of primary tumors measured at the time of tumor excision on day 21, and the lung metastasis of melanoma cells as compared with the untreated control in the spontaneous metastasis model. These results suggested that the suppressive effect upon tumor-associated angiogenesis by DT-5461 contributes in part to the inhibition of tumor metastasis.
我们研究了一种低内毒素合成脂多糖类似物DT - 5461对同基因小鼠中B16 - BL6黑色素瘤诱导的新生血管形成的影响。在血管生成早期(肿瘤接种后第4天),全身性单次给予DT - 5461导致朝向肿瘤块的血管数量和肿瘤大小显著减少,而在随后阶段几乎没有抑制作用。以4天的间隔多次静脉注射DT - 5461(抑制肿瘤转移的有效方案)在肿瘤植入后的14天内显著减少了毛细血管数量和肿瘤生长。在肿瘤接种后的第1、5和9天多次全身性给予DT - 5461,导致肿瘤部位内源性肿瘤坏死因子 - α(TNF - α)大量产生,尽管这种治疗方式在荷瘤小鼠血清中诱导产生的量较低。用DT - 5461处理的小鼠的肿瘤匀浆在体外抑制内皮细胞增殖,而给予DT - 5461的动物的血清几乎没有作用。此外,用抗mTNF - α单克隆抗体(mAb)可完全消除用DT - 5461处理的小鼠的肿瘤匀浆的抗增殖作用。DT - 5461的抗血管生成作用也被兔抗小鼠肿瘤坏死因子 - α(抗mTNF - α)抗血清完全消除,而DT - 5461对肿瘤生长的抑制作用仅略有减弱。用DT - 5461处理的小鼠的肿瘤匀浆在体外抑制内皮细胞增殖,而给予DT - 5461的动物的血清几乎没有作用。此外,用抗mTNF - α mAb可完全中和用DT - 5461处理的小鼠的肿瘤匀浆的抗增殖作用。在皮下植入B16 - BL6细胞后多次静脉注射DT - 5461,与自发转移模型中的未处理对照相比,在第21天肿瘤切除时测量的原发性肿瘤生长以及黑色素瘤细胞的肺转移均受到显著抑制。这些结果表明,DT - 5461对肿瘤相关血管生成的抑制作用部分有助于抑制肿瘤转移。